West Pharmaceutical Services (NYSE:WST) Issues Earnings Results, Beats Expectations By $0.29 EPS

West Pharmaceutical Services (NYSE:WST) released its quarterly earnings results on Thursday. The medical instruments supplier reported $2.37 earnings per share for the quarter, beating analysts’ consensus estimates of $2.08 by $0.29, Zacks reports. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The business had revenue of $872.30 million during the quarter, compared to analyst estimates of $839.98 million. During the same period last year, the business earned $1.84 EPS. The business’s revenue was up 13.8% on a year-over-year basis. West Pharmaceutical Services updated its Q3 2026 guidance to 2.140-2.240 EPS and its FY 2026 guidance to 8.850-9.050 EPS.

Here are the key takeaways from West Pharmaceutical Services’ conference call:

• West delivered Q2 2026 results above expectations, with revenue of $872 million up 13% organically and adjusted EPS of $2.37 up 29% year over year.
• The company raised full-year guidance to 10%-11% organic revenue growth and adjusted EPS of $8.85-$9.05, citing strong momentum in the business.
• High-value product components were the main growth engine, with organic growth of 18% led by biologics, Annex 1-related upgrades, and GLP-1 demand. Management said non-GLP-1 HVP components outperformed expectations and still have a multi-year runway.
• The cyber incident still affected West Vantage, holding Q2 growth to 1% and shifting some revenue into the second half. Management said the impact should be made up later this year, with Q3 expected to be the trough for the segment.
• Gross margin and operating margin both improved meaningfully in the quarter, helped by stronger sales mix, pricing, and leverage from higher revenue. West also continued share repurchases, buying back $157 million of stock in Q2.

West Pharmaceutical Services Stock Up 0.0%

NYSE WST traded up $0.16 on Thursday, hitting $358.57. 596,589 shares of the stock traded hands, compared to its average volume of 896,692. The company has a current ratio of 2.71, a quick ratio of 2.04 and a debt-to-equity ratio of 0.07. The stock has a 50-day moving average of $335.41 and a 200 day moving average of $286.58. West Pharmaceutical Services has a twelve month low of $223.83 and a twelve month high of $386.00. The company has a market capitalization of $25.33 billion, a P/E ratio of 47.74, a price-to-earnings-growth ratio of 2.91 and a beta of 1.16.

West Pharmaceutical Services Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th will be paid a dividend of $0.22 per share. The ex-dividend date is Wednesday, July 29th. This represents a $0.88 annualized dividend and a yield of 0.2%. West Pharmaceutical Services’s dividend payout ratio is presently 11.76%.

West Pharmaceutical Services News Roundup

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: West Pharmaceutical posted Q2 2026 EPS of $2.37, ahead of the $2.08 consensus, while revenue of $872.3 million also topped estimates. The beat suggests strong operating momentum and is a key reason investors are bidding up the stock. West Pharmaceutical Services (NYSE:WST) Beats Expectations in Strong Q2 CY2026, Stock Soars
• Positive Sentiment: The company raised its 2026 outlook, guiding EPS to $8.85-$9.05 versus the prior/consensus view around $8.61, and revenue to about $3.3 billion-$3.4 billion. Higher guidance often supports the stock because it signals confidence in continued demand and earnings growth. West Pharmaceutical raises annual profit forecast on strong demand for injectable drug components
• Positive Sentiment: Management also lifted Q3 2026 guidance, forecasting EPS of $2.14-$2.24 and revenue of $820 million-$835 million, both modestly above expectations. This reinforces the view that the earnings beat was not a one-quarter event.
• Positive Sentiment: Reuters noted demand remains strong for injectable-drug components tied to diabetes and obesity treatments, a favorable end-market trend that could continue to support West’s growth.

Insider Buying and Selling

In other West Pharmaceutical Services news, VP Annette F. Favorite sold 2,817 shares of West Pharmaceutical Services stock in a transaction on Monday, April 27th. The shares were sold at an average price of $305.20, for a total value of $859,748.40. Following the completion of the transaction, the vice president owned 16,828 shares of the company’s stock, valued at $5,135,905.60. The trade was a 14.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CAO Chad Winters sold 896 shares of the business’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $300.67, for a total transaction of $269,400.32. Following the sale, the chief accounting officer owned 1,523 shares of the company’s stock, valued at approximately $457,920.41. The trade was a 37.04% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On West Pharmaceutical Services

A number of large investors have recently bought and sold shares of WST. Empowered Funds LLC raised its position in shares of West Pharmaceutical Services by 16.1% during the 1st quarter. Empowered Funds LLC now owns 1,611 shares of the medical instruments supplier’s stock worth $361,000 after purchasing an additional 224 shares during the period. Intech Investment Management LLC grew its stake in West Pharmaceutical Services by 27.7% during the 1st quarter. Intech Investment Management LLC now owns 6,020 shares of the medical instruments supplier’s stock worth $1,348,000 after buying an additional 1,307 shares during the last quarter. Acadian Asset Management LLC increased its position in West Pharmaceutical Services by 14.1% in the first quarter. Acadian Asset Management LLC now owns 1,271 shares of the medical instruments supplier’s stock worth $284,000 after buying an additional 157 shares during the period. EverSource Wealth Advisors LLC increased its position in West Pharmaceutical Services by 78.2% in the second quarter. EverSource Wealth Advisors LLC now owns 449 shares of the medical instruments supplier’s stock worth $98,000 after buying an additional 197 shares during the period. Finally, First Trust Advisors LP lifted its stake in West Pharmaceutical Services by 168.4% in the second quarter. First Trust Advisors LP now owns 46,332 shares of the medical instruments supplier’s stock valued at $10,137,000 after buying an additional 29,067 shares during the last quarter. Institutional investors own 93.90% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on WST shares. Stephens restated an “overweight” rating and set a $360.00 target price on shares of West Pharmaceutical Services in a research note on Tuesday, June 2nd. Evercore reissued an “outperform” rating and issued a $410.00 price target on shares of West Pharmaceutical Services in a report on Monday, July 6th. KeyCorp raised their price objective on West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “overweight” rating in a research note on Thursday, July 2nd. TD Cowen reaffirmed a “buy” rating on shares of West Pharmaceutical Services in a research report on Wednesday, July 15th. Finally, Zacks Research raised shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, May 13th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, West Pharmaceutical Services currently has an average rating of “Buy” and a consensus target price of $363.17.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.